AFT Pharmaceuticals Limited

AFT

NZAFTE0001S4

Pharmaceuticals

End-of-day quote New Zealand S.E. Other stock markets 06:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
2.94 ^NZD	-3.61%		-3.61%	-16.00%

Jul. 09	New Zealand Shares Jump on US Rate Cut Optimism; AFT Pharmaceuticals to Launch Topical Medication in China	MT
Jul. 09	AFT Pharmaceuticals to Launch Skin Infection Cream in China	MT

AFT Pharmaceuticals Limited Extends Maxigesic IV License in South America

May 04, 2021 at 03:44 pm EDT

AFT Pharmaceuticals Limited announced it has licensed Maxigesic IV into Colombia, Peru, Chile, Ecuador, Bolivia, and Uruguay, extending the medicine's addressable market in Latin America and the Caribbean to 17 countries. The agreement with Pharma Bavaria International builds on an agreement signed in February 2020, that saw Maxigesic IV licensed to the German company in 12 countries in Central America and the Caribbean including Panama, Costa Rica, El Salvador, Honduras, Nicaragua, Guatemala, Belize, the Dominican Republic, Haiti, Trinidad & Tobago, and Cuba.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	MSCI PERU (GDTR)	9,365 PTS	-0.73%	-1.61%	-
	NASDAQ COLOMBIA	361.3 PTS	-1.57%	-0.98%	-

Latest news about AFT Pharmaceuticals Limited

New Zealand Shares Jump on US Rate Cut Optimism; AFT Pharmaceuticals to Launch Topical Medication in China	Jul. 09	MT
AFT Pharmaceuticals to Launch Skin Infection Cream in China	Jul. 08	MT
AFT Pharmaceuticals Announces an Agreement with Hainan Haiyao Co. Ltd to Distribute Crystaderm® Cream in China	Jul. 08	CI
AFT Pharmaceuticals Limited Announces Retirement of Anita Baldauf as Independent Director	Jun. 30	CI
New Zealand Shares Flat; Scott Technology Adds Meat Cutter to Brand Portfolio	Jun. 04	MT
AFT Pharmaceuticals Partners with Alexso to Bring Pain Relief Drug to US Market	Jun. 03	MT
AFT Pharmaceuticals Limited to Launch Maxigesic Rapid in the United States	Jun. 03	CI
AFT Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 23	CI
Transcript : AFT Pharmaceuticals Limited, 2024 Earnings Call, May 23, 2024	May. 22
AFT Pharmaceuticals' Net Profit Climbs 46% in Fiscal 2024; Dividend Declared	May. 22	MT
AFT Pharmaceuticals Limited Announces Ordinary Dividend for the Twelve Months Ended Mach 31, 2024, Payable on July 4, 2024	May. 22	CI
AFT Pharmaceuticals Signs Brazil Licensing Agreement for Maxigesic IV	Apr. 30	MT
AFT Pharmaceuticals Limited Licenses Maxigesic IV in Brazil	Apr. 30	CI
New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment	Apr. 24	MT
AFT Pharmaceuticals, Massey Ventures, Gillies McIndoe Research Institute Partner to Develop Topical Scar Treatment	Apr. 24	MT
AFT Pharmaceuticals Limited, Massey Ventures, Gilles Mcindoe Research Institute to Develop Scar Treatment	Apr. 23	CI
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down	Mar. 03	MT
AFT Pharmaceuticals to Expand Global Footprint with Signing of Supply, Production Deals	Mar. 03	MT
Aft Expands Its Co-Operation with Hikma Pharmaceuticals	Mar. 03	CI
New Zealand Shares Rebound on Friday Close; AFT Pharmaceuticals Raises Operation Profit Guidance	Feb. 15	MT
AFT Pharmaceuticals Boosts Operating Profit Guidance for Fiscal Year 2024	Feb. 15	MT
AFT Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024	Feb. 15	CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4%	Feb. 06	MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US	Feb. 05	MT
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication	Jan. 18	MT

Chart AFT Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.

Sector

Pharmaceuticals

Calendar

2024-08-01 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for AFT Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.94 NZD

Average target price

3.75 NZD

Spread / Average Target

+27.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AFT PHARMACEUTICALS LIMITED	-16.00%	187M
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.07%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.49%	247B
NOVARTIS AG	+14.94%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals